BRCA1 and cancer: These data demonstrated that regulation of 53BP1 by the ASCIZ-DYNLL1 axis supports the efficacy of olaparib treatments in selectively killing Brca1-deficient cancer cells, confirming the importance of DYNLL1-53BP1 interactions in regulating 53BP1-dependent DNA repair.